Covalon Technologies Ltd. to Participate in the 2024 Association for Vascular Access Annual Scientific Meeting
Covalon Technologies (TSXV: COV; OTCQX: CVALF) announces its participation in the 2024 Association for Vascular Access (AVA) Annual Scientific Meeting from September 28 to 30 in Colorado. The company will showcase its compassionate vascular access solutions at booth #523, including a new range of CovaClear® IV Vascular Access Dressings.
Covalon's patented products on display include:
- VALGuard® - a transparent line guard
- SurgiClear® - a dual antimicrobial clear silicone adhesive dressing
- IV Clear® - a dual antimicrobial clear IV securement dressing
- CovaClear® IV - a soft silicone adhesive clear IV dressing
CEO Brent Ashton emphasizes the company's commitment to enhancing patient comfort and improving vascular access clinical care. Attendees can book appointments with Covalon representatives to learn more about their innovative solutions.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) annuncia la sua partecipazione alla 2024 Association for Vascular Access (AVA) Annual Scientific Meeting che si svolgerà dal 28 al 30 settembre in Colorado. L'azienda presenterà le sue soluzioni compassionevoli per l'accesso vascolare allo stand #523, tra cui una nuova gamma di bendaggi per accesso vascolare CovaClear® IV.
I prodotti brevettati di Covalon in esposizione includono:
- VALGuard® - un protettore trasparente
- SurgiClear® - un bendaggio adesivo in silicone chiaro antimicrobico duale
- IV Clear® - un bendaggio sicuro per IV chiaro e antimicrobico duale
- CovaClear® IV - un bendaggio adesivo chiaro in silicone morbido per IV
Il CEO Brent Ashton sottolinea l'impegno dell'azienda nel migliorare il comfort dei pazienti e nel perfezionare la cura clinica per l'accesso vascolare. I partecipanti possono prenotare appuntamenti con i rappresentanti di Covalon per saperne di più sulle loro soluzioni innovative.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) anuncia su participación en la 2024 Association for Vascular Access (AVA) Annual Scientific Meeting que se llevará a cabo del 28 al 30 de septiembre en Colorado. La compañía presentará sus soluciones compasivas para el acceso vascular en el stand #523, incluyendo una nueva gama de apósitos para acceso vascular CovaClear® IV.
Los productos patentados de Covalon en exhibición incluyen:
- VALGuard® - una protección transparente
- SurgiClear® - un apósito adhesivo de silicona clara con doble acción antimicrobiana
- IV Clear® - un apósito seguro para IV claro y con doble acción antimicrobiana
- CovaClear® IV - un apósito adhesivo claro de silicona suave para IV
El CEO Brent Ashton enfatiza el compromiso de la empresa en mejorar la comodidad del paciente y en optimizar la atención clínica del acceso vascular. Los asistentes pueden reservar citas con los representantes de Covalon para conocer más sobre sus innovadoras soluciones.
Covalon Technologies (TSXV: COV; OTCQX: CVALF)는 2024년 혈관 접근 협회 (AVA) 연례 과학 회의에 참가한다고 발표했습니다. 이 회의는 9월 28일부터 30일까지 콜로라도에서 열리며, 회사는 부스 #523에서 CovaClear® IV 혈관 접근 드레싱을 포함한 자애적인 혈관 접근 솔루션을 선보일 것입니다.
전시될 Covalon의 특허 제품은 다음과 같습니다:
- VALGuard® - 투명 라인 가드
- SurgiClear® - 이중 항균 투명 실리콘 접착 드레싱
- IV Clear® - 이중 항균 IV 고정 드레싱
- CovaClear® IV - 부드러운 실리콘 접착 투명 IV 드레싱
CEO Brent Ashton은 회사가 환자의 편안함을 향상시키고 혈관 접근 임상 치료를 개선하기 위해 최선을 다하고 있다고 강조했습니다. 참석자는 Covalon 대표와의 상담을 예약하여 그들의 혁신적인 솔루션에 대해 더 많이 배울 수 있습니다.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) annonce sa participation à la 2024 Association for Vascular Access (AVA) Annual Scientific Meeting qui se tiendra du 28 au 30 septembre dans le Colorado. L'entreprise présentera ses solutions compassionnelles pour l'accès vasculaire au stand #523, y compris une nouvelle gamme de pansements d'accès vasculaire CovaClear® IV.
Les produits brevetés de Covalon exposés comprennent :
- VALGuard® - une protection transparente
- SurgiClear® - un pansement adhésif en silicone clair à double action antimicrobienne
- IV Clear® - un pansement intraveineux clair et sécurisé à double action antimicrobienne
- CovaClear® IV - un pansement intraveineux adhésif clair en silicone doux
Le PDG Brent Ashton souligne l'engagement de l'entreprise à améliorer le confort des patients et à optimiser les soins cliniques pour l'accès vasculaire. Les participants peuvent réserver des rendez-vous avec des représentants de Covalon pour en savoir plus sur leurs solutions innovantes.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) gibt ihre Teilnahme an der 2024 Association for Vascular Access (AVA) Annual Scientific Meeting bekannt, die vom 28. bis 30. September in Colorado stattfindet. Das Unternehmen wird seine einfühlsamen Lösungen für den vaskulären Zugang am Stand #523 präsentieren, einschließlich einer neuen Reihe von CovaClear® IV-Vaskulären Zugangsdressings.
Ausgestellte patentierte Produkte von Covalon sind:
- VALGuard® - ein transparenter Schutz
- SurgiClear® - ein dualantimikrobielles durchsichtiges Silikonhaftpflaster
- IV Clear® - ein dualantimikrobielles, sicheres IV-Dressing
- CovaClear® IV - ein weiches, transparentes Silikon-IV-Dressing
CEO Brent Ashton hebt das Engagement des Unternehmens hervor, den Komfort der Patienten zu verbessern und die klinische Pflege für den vaskulären Zugang zu optimieren. Teilnehmer können Termine mit Covalon-Vertretern buchen, um mehr über ihre innovativen Lösungen zu erfahren.
- None.
- None.
Visit Covalon at booth 523 to discover the latest in compassionate vascular access solutions
(Photo: Business Wire)
“Our participation in the AVA Annual Scientific Meeting highlights Covalon’s commitment to enhancing patient comfort and supporting improved vascular access clinical care,” said Brent Ashton, Chief Executive Officer, Covalon. “Our silicone-adhesive dressings help to reduce the challenges of cumbersome acrylic dressing removals, while our vascular access line guard helps to protect against gross contamination. Together, these products combine safety, compassion, and innovation to help improve clinical outcomes."
At booth #523, Covalon will be showcasing its comprehensive range of compassionate vascular access solutions, including a new range of CovaClear® IV Vascular Access Dressings. Attendees are invited to learn more about how these innovative products are helping healthcare providers deliver exceptional care to patients around the world. Covalon representatives will be available to discuss the latest advancements in vascular access technology and answer any questions.
Covalon’s patented vascular access products include:
- VALGuard® - a transparent line guard designed to protect IV line connections and hubs from external contaminants, including body fluids and other secretions.
- SurgiClear® - a dual antimicrobial clear silicone adhesive dressing with Chlorhexidine and Silver used to cover and protect wound sites and wound closure devices.
- IV Clear® - a dual antimicrobial (Chlorhexidine and Silver) clear IV securement dressing that provides antimicrobial protection throughout the entire dressing surface area.
- CovaClear® IV - a soft silicone adhesive clear IV dressing that helps protect insertion sites from external contaminants. Suitable for patients who either don’t require, or cannot tolerate, antimicrobials.
Scheduling Appointments and Additional Information
To book an appointment with a Covalon representative, please email Ron Hebert, SVP Growth, Covalon Technologies Ltd., at rhebert@covalon.com.
Conference Details
- Dates: September 28 – 30 2024
-
Location: Gaylord Rockies Resort & Convention Center, 6700 N Gaylord Rockies Blvd,
Aurora, CO 80019,United States - Registration: https://avasm24.eventscribe.net
For healthcare providers unable to attend the conference, Covalon encourages you to visit www.covalon.com or follow the company on LinkedIn, Facebook, or Instagram to learn more about its solutions.
About Covalon
Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions for advanced wound care, infection control, and medical device coatings. Through a strong portfolio of patented technologies and solutions, we offer innovative, gentle and more compassionate options to aid patients on their healing journey. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2023, which is available on the Company’s profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240927012827/en/
To learn more about Covalon, please contact:
Investor Relations, Covalon Technologies Ltd.
Email: investors@covalon.com
Website: https://covalon.com/
Source: Covalon Technologies Ltd.
FAQ
When and where is Covalon Technologies (CVALF) participating in the AVA Annual Scientific Meeting?
What products will Covalon Technologies (CVALF) showcase at the 2024 AVA Annual Scientific Meeting?
How can healthcare providers book an appointment with Covalon Technologies (CVALF) at the 2024 AVA Annual Scientific Meeting?
What is the purpose of Covalon Technologies 's (CVALF) participation in the 2024 AVA Annual Scientific Meeting?
